Pharmacy Life

Pharmacy Life Health Education & Pharmacovigilance

đź’Š PHARMACY LIFE | THE SCIENCE OF YOUR HEALTHHERBAL DOESN'T ALWAYS MEAN HARMLESS.When you hear the word herbal, what come...
27/10/2026

đź’Š PHARMACY LIFE | THE SCIENCE OF YOUR HEALTH

HERBAL DOESN'T ALWAYS MEAN HARMLESS.

When you hear the word herbal, what comes to mind? For many people, it means natural, gentle, and safe.

But here's something worth understanding: natural products can contain biologically active substances that cause side effects or interact with prescription medicines. Some products may also contain undeclared pharmaceutical ingredients.

This is why your pharmacist needs to know about everything you take, including herbal mixtures, supplements, and traditional preparations.

Never stop prescribed treatment or combine medicines with herbal products without seeking appropriate professional advice.

Remember: Knowing what is inside a product is just as important as knowing what it claims to treat.

đź’¬ Have you ever wondered whether herbal medicines can interact with hospital-prescribed medicines? Share your questions in the comments.

PHARMACY LIFE
Medicines. Science. Policy. People.

🌍 PHARMACY LIFE | GLOBAL PHARMA NEWSBREAKING DEVELOPMENT: US FDA APPROVES ONCE-WEEKLY INSULIN FOR CHILDREN WITH TYPE 2 D...
26/10/2026

🌍 PHARMACY LIFE | GLOBAL PHARMA NEWS

BREAKING DEVELOPMENT: US FDA APPROVES ONCE-WEEKLY INSULIN FOR CHILDREN WITH TYPE 2 DIABETES

The United States Food and Drug Administration has approved Awiqli (insulin icodec-abae) as the first once-weekly insulin treatment for paediatric patients with type 2 diabetes.

The approval, announced on 23 October 2026, marks an important development in diabetes pharmacotherapy.

Traditionally, insulin treatment has often required daily injections, depending on the insulin preparation and the patient's treatment plan. A once-weekly formulation could offer a different approach to insulin administration for eligible patients.

However, less frequent administration does not automatically mean that treatment is simpler or safer for every patient. Insulin remains a high-risk medicine, and appropriate prescribing, glucose monitoring, dose selection and patient education remain essential.

For children and adolescents living with diabetes, treatment decisions must also consider their developmental needs, family support and individual clinical circumstances.

🇬🇭 WHAT DOES THIS MEAN FOR GHANA?

This is an important international regulatory development, but US FDA approval does not automatically establish approval, registration or availability in Ghana.

The implications for Ghanaian patients will depend on local regulatory status, clinical suitability, affordability and access.

As pharmaceutical innovation advances, the challenge remains ensuring that new treatment options translate into safe, meaningful benefits for patients.

Question for pharmacists and healthcare professionals: What factors should be considered before introducing a new long-acting insulin formulation into clinical practice?

Follow Pharmacy Life for pharmaceutical news, clinical developments and healthcare policy updates.

Address

Accra

Website

Alerts

Be the first to know and let us send you an email when Pharmacy Life posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Share